01—Abstract
Summary
Summary of the 8-K filed December 11, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. announced on December 11, 2020, that the U.S. government exercised its option to purchase an additional 100 million doses of its COVID-19 vaccine candidate, mRNA-1273.
This expansion of the initial agreement, which was dated August 11, 2020, significantly increases the potential supply commitment for Moderna's vaccine. The amendment to the U.S. Supply Agreement also allows the U.S. government to exercise this option before the vaccine receives Emergency Use Authorization (EUA) from the FDA. This proactive move by the government underscores the urgent demand for effective COVID-19 vaccines and strengthens Moderna's commercial outlook.
02—Key points
Key Highlights
- U.S. government exercised an option to purchase an additional 100 million doses of mRNA-1273.
- This order increases the total potential U.S. government commitment for Moderna's COVID-19 vaccine.
- The amendment allows the option exercise prior to FDA Emergency Use Authorization (EUA).
- The purchase is under an existing agreement dated August 11, 2020, with the Army Contracting Command.
- This announcement suggests strong government confidence and commitment to Moderna's vaccine development.
- The filing includes a press release detailing this significant development.
03—Questions
Frequently Asked Questions
What is the significance of the U.S. government purchasing additional doses?
The purchase of an additional 100 million doses by the U.S. government indicates strong demand and significant commitment to Moderna's mRNA-1273 vaccine. It also bolsters Moderna's revenue potential and solidifies its position in the COVID-19 vaccine market.
Why was the option exercised before FDA authorization?
Exercising the option prior to FDA Emergency Use Authorization (EUA) demonstrates the U.S. government's urgency and proactive approach to securing vaccine supply in anticipation of regulatory approval and widespread need.
How does this affect Moderna's overall supply commitments?
This additional order substantially increases the total number of doses the U.S. government has committed to purchasing from Moderna, positively impacting the company's manufacturing scale-up and future revenue projections.
What is the role of the amendment to the U.S. Supply Agreement?
The amendment allows the U.S. government to exercise its option to purchase more doses even before the FDA has granted an Emergency Use Authorization for mRNA-1273. This flexibility is crucial for rapid deployment once approval is obtained.
04—Continue